Aditya Badheka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aditya Badheka has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Madhuradhar Chegondi
University of Illinois College of Medicine
12 shared publications Veerajalandhar Allareddy
Division of Pediatric Critical Care, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
12 shared publicationsPradeep Bangalore Prakash
Mercy Medical Center, Des Moines, Iowa, USA
5 shared publicationsVeerasathpurush Allareddy
Department of Orthodontics, College of Dentistry, University of Illinois at Chicago, Chicago, IL, USA
5 shared publicationsSankeerth Rampa
Health Care Administration, Rhode Island College, Providence, Rhode Island, USA
4 shared publicationsJodi Bloxham
Division of Pediatric Critical Care, Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, USA
3 shared publications
Latest Publications
- 1 December 2026
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 331 (6) , H2151-H2157
Derivation of pulse wave velocity from arterial waveforms in children
Our study provides a method for estimating PWV in children from arterial waveforms without tonometry. We used gold-standard tonometry to measure brachio-femoral or carotid-femoral PWV and derived an equation to estimate effective reflecting distance (EfRD) and PWV from arterial waveforms in a pediatric critical care setting. We determined that PWV can be estimated from arterial waveforms, providing a new tool for studying aortic stiffness in pediatric patients at risk for cardiovascular disease.
- 1 December 2026
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 331 (6) , H2151-H2157
Derivation of pulse wave velocity from arterial waveforms in children
Our study provides a method for estimating PWV in children from arterial waveforms without tonometry. We used gold-standard tonometry to measure brachio-femoral or carotid-femoral PWV and derived an equation to estimate effective reflecting distance (EfRD) and PWV from arterial waveforms in a pediatric critical care setting. We determined that PWV can be estimated from arterial waveforms, providing a new tool for studying aortic stiffness in pediatric patients at risk for cardiovascular disease.
- 18 April 2026
- Published by SAGE Publications in Perfusion
- Vol. 41 (5) , 600-607
Association between platelet indices and next-day bleeding and clotting in children and adults on extracorporeal membrane oxygenation: A retrospective study
Introduction: Bleeding and clotting phenotypes are common in patients supported with Extracorporeal Membrane Oxygenation (ECMO) and are associated with increased mortality. However, tools to distinguish bleeding from clotting phenotypes remain limited. Readily available platelet indices may help characterize these phenotypes. Methods: We retrospectively studied patients admitted to neonatal, pediatric, and adult intensive care units (ICUs) at two centers from 2018 to 2022, who were on ECMO and required platelet transfusions. The association between pre-transfusion platelet indices (platelet count, mean platelet volume, platelet mass index) and bleeding or clotting on subsequent day was assessed with day-level univariable and multivariable logistic regression models. Results: We enrolled 268 patients receiving ECMO support (75% veno-arterial), with a median age was 51 years (IQR 18.9–65.6). A total of 1395 platelet transfusion events were analyzed, of which 18% were followed by bleeding and 5% by thrombosis within 24 h. After multivariable adjustment, higher pre-transfusion platelet counts independently associated with subsequent bleeding (adjusted odds ratio [aOR] 1.001, p = 0.03) but not with subsequent thrombosis (aOR 0.99, p = 0.18). Lower pre-transfusion mean platelet volume (MPV) were independently associated with increased bleeding risk (aOR 0.87, p = 0.049), while MPV was not associated with thrombosis (aOR 1.03, p = 0.47). Platelet mass index (PMI) was not independently associated with bleeding (aOR 1.00, p = 0.80) or thrombosis (aOR 1.00, p = 0.32). All platelet indices demonstrated poor discriminatory performance for predicting bleeding or thrombosis, with area under the curve values ranging from 0.42 to 0.55. Conclusions: Although platelet count and MPV were independently associated with subsequent bleeding, neither index reliably distinguished bleeding phenotypes. Improved tools are needed to predict hemostatic outcomes in patients supported with ECMO.
- 18 April 2026
- Published by SAGE Publications in Perfusion
- Vol. 41 (5) , 600-607
Association between platelet indices and next-day bleeding and clotting in children and adults on extracorporeal membrane oxygenation: A retrospective study
Introduction: Bleeding and clotting phenotypes are common in patients supported with Extracorporeal Membrane Oxygenation (ECMO) and are associated with increased mortality. However, tools to distinguish bleeding from clotting phenotypes remain limited. Readily available platelet indices may help characterize these phenotypes. Methods: We retrospectively studied patients admitted to neonatal, pediatric, and adult intensive care units (ICUs) at two centers from 2018 to 2022, who were on ECMO and required platelet transfusions. The association between pre-transfusion platelet indices (platelet count, mean platelet volume, platelet mass index) and bleeding or clotting on subsequent day was assessed with day-level univariable and multivariable logistic regression models. Results: We enrolled 268 patients receiving ECMO support (75% veno-arterial), with a median age was 51 years (IQR 18.9–65.6). A total of 1395 platelet transfusion events were analyzed, of which 18% were followed by bleeding and 5% by thrombosis within 24 h. After multivariable adjustment, higher pre-transfusion platelet counts independently associated with subsequent bleeding (adjusted odds ratio [aOR] 1.001, p = 0.03) but not with subsequent thrombosis (aOR 0.99, p = 0.18). Lower pre-transfusion mean platelet volume (MPV) were independently associated with increased bleeding risk (aOR 0.87, p = 0.049), while MPV was not associated with thrombosis (aOR 1.03, p = 0.47). Platelet mass index (PMI) was not independently associated with bleeding (aOR 1.00, p = 0.80) or thrombosis (aOR 1.00, p = 0.32). All platelet indices demonstrated poor discriminatory performance for predicting bleeding or thrombosis, with area under the curve values ranging from 0.42 to 0.55. Conclusions: Although platelet count and MPV were independently associated with subsequent bleeding, neither index reliably distinguished bleeding phenotypes. Improved tools are needed to predict hemostatic outcomes in patients supported with ECMO.
- 23 December 2025
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (3) , 410-421
Platelet Transfusion Thresholds for Children Supported by Extracorporeal Membrane Oxygenation: The Extracorporeal Membrane Oxygenation Hemostatic Transfusions in Children (ECSTATIC) Feasibility Clinical Trial
Objectives: To evaluate the feasibility of randomizing children on extracorporeal membrane oxygenation (ECMO) to one of two prophylactic platelet transfusion thresholds. Design: Randomized controlled trial. Setting: Ten ECMO centers (nine in United States, one in Israel). Patients: Critically ill children (0 to younger than 18 yr), supported on ECMO, with no or minimal bleeding within 24 hours of cannulation. Interventions: Children were randomized to a higher platelet threshold (transfused when platelet count < 90 × 10 9 /L) or a lower platelet threshold (transfused when platelet count < 50 × 10 9 /L). Primary feasibility outcome was pre-transfusion platelet count to test for a difference between strategies. Primary safety outcome was progression to severe bleeding, severe clotting, and/or all-cause mortality. Measurements and Main Results: Of 159 patients screened for eligibility, 77% (123/159) met eligibility criteria. Sixty-five percent (80/123) of caregivers were approached for consent. Consent was obtained in 63% (50/80). Enrolled children had a median age of 0.2 years (interquartile range 0.0; 1.7) and 88% (44/50) were supported by veno-arterial (V-A) ECMO. The model-adjusted mean difference in pre-transfusion platelet count between the groups was 32 × 10 9 /L ( p < 0.001). Compliance with assigned transfusion threshold was 99.2%. Eleven (22%) children experienced the primary safety outcome. Progression to severe bleeding occurred in 14% (7/50) of patients, whereas progression to severe clotting was observed in 4% (2/50). Conclusions: Non-bleeding children on ECMO can be screened, enrolled and randomized to different platelet transfusion strategies within 24 hours of cannulation. Compliance with the protocol was excellent with significant separation in pre-transfusion platelet counts between the arms. Severe bleeding and severe clotting occurred at similar rates in both thresholds. A larger, definitive trial is feasible and needed.
- 23 December 2025
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (3) , 410-421
Platelet Transfusion Thresholds for Children Supported by Extracorporeal Membrane Oxygenation: The Extracorporeal Membrane Oxygenation Hemostatic Transfusions in Children (ECSTATIC) Feasibility Clinical Trial
Objectives: To evaluate the feasibility of randomizing children on extracorporeal membrane oxygenation (ECMO) to one of two prophylactic platelet transfusion thresholds. Design: Randomized controlled trial. Setting: Ten ECMO centers (nine in United States, one in Israel). Patients: Critically ill children (0 to younger than 18 yr), supported on ECMO, with no or minimal bleeding within 24 hours of cannulation. Interventions: Children were randomized to a higher platelet threshold (transfused when platelet count < 90 × 10 9 /L) or a lower platelet threshold (transfused when platelet count < 50 × 10 9 /L). Primary feasibility outcome was pre-transfusion platelet count to test for a difference between strategies. Primary safety outcome was progression to severe bleeding, severe clotting, and/or all-cause mortality. Measurements and Main Results: Of 159 patients screened for eligibility, 77% (123/159) met eligibility criteria. Sixty-five percent (80/123) of caregivers were approached for consent. Consent was obtained in 63% (50/80). Enrolled children had a median age of 0.2 years (interquartile range 0.0; 1.7) and 88% (44/50) were supported by veno-arterial (V-A) ECMO. The model-adjusted mean difference in pre-transfusion platelet count between the groups was 32 × 10 9 /L ( p < 0.001). Compliance with assigned transfusion threshold was 99.2%. Eleven (22%) children experienced the primary safety outcome. Progression to severe bleeding occurred in 14% (7/50) of patients, whereas progression to severe clotting was observed in 4% (2/50). Conclusions: Non-bleeding children on ECMO can be screened, enrolled and randomized to different platelet transfusion strategies within 24 hours of cannulation. Compliance with the protocol was excellent with significant separation in pre-transfusion platelet counts between the arms. Severe bleeding and severe clotting occurred at similar rates in both thresholds. A larger, definitive trial is feasible and needed.
- 16 October 2025
- Published by SAGE Publications in Perfusion
- Vol. 41 (6) , 917-927
Flow monitoring of venovenous and venoarterial ECMO to detect circuit obstructions using hemodynamic modeling
Introduction: Current extracorporeal membrane oxygenation (ECMO) monitoring methods for circuit obstructions have limitations. In this study, we test the hypothesis that changes in flow in a pre-existing shunt tubing of the ECMO circuit can be used as a predictor of obstructions for both venovenous (V-V) and venoarterial ECMO (V-A ECMO) circuits using a computational hemodynamic model. Methods: A custom computational hemodynamic model (CHM) representing the blood flow within the V-A ECMO and V-V ECMO circuit and native cardiovascular system was developed for a hemodynamic parametric analysis. Several degrees of obstructions within the oxygenator and outlet cannula were simulated, and the flow in the ECMO circuit and shunt was monitored to assess its sensitivity to circuit obstructions. Over 500 cases were analyzed to investigate various clinically-relevant levels of ECMO support (2 – 5.5 L/min). Results: Our model demonstrated that shunt flow changed linearly with increasing oxygenator obstruction for all oxygenator obstruction scenarios tested, which matched experimental data. Similar relationships were also seen for all outflow cannula obstructions. Conclusions: The findings are consistent with our hypothesis, indicating the sensitivity of the shunt flow rate as a predictor of ECMO circuit obstructions for both V-A and V-V ECMO circuits. The data supports that shunt flow responds to hemodynamic changes throughout the ECMO-patient circuit and thus can be used as an early indicator for ECMO system obstructions regardless of V-A or V-V ECMO setup, indicating its robustness as an early warning indicator of ECMO system obstructions.
- 16 October 2025
- Published by SAGE Publications in Perfusion
- Vol. 41 (6) , 917-927
Flow monitoring of venovenous and venoarterial ECMO to detect circuit obstructions using hemodynamic modeling
Introduction: Current extracorporeal membrane oxygenation (ECMO) monitoring methods for circuit obstructions have limitations. In this study, we test the hypothesis that changes in flow in a pre-existing shunt tubing of the ECMO circuit can be used as a predictor of obstructions for both venovenous (V-V) and venoarterial ECMO (V-A ECMO) circuits using a computational hemodynamic model. Methods: A custom computational hemodynamic model (CHM) representing the blood flow within the V-A ECMO and V-V ECMO circuit and native cardiovascular system was developed for a hemodynamic parametric analysis. Several degrees of obstructions within the oxygenator and outlet cannula were simulated, and the flow in the ECMO circuit and shunt was monitored to assess its sensitivity to circuit obstructions. Over 500 cases were analyzed to investigate various clinically-relevant levels of ECMO support (2 – 5.5 L/min). Results: Our model demonstrated that shunt flow changed linearly with increasing oxygenator obstruction for all oxygenator obstruction scenarios tested, which matched experimental data. Similar relationships were also seen for all outflow cannula obstructions. Conclusions: The findings are consistent with our hypothesis, indicating the sensitivity of the shunt flow rate as a predictor of ECMO circuit obstructions for both V-A and V-V ECMO circuits. The data supports that shunt flow responds to hemodynamic changes throughout the ECMO-patient circuit and thus can be used as an early indicator for ECMO system obstructions regardless of V-A or V-V ECMO setup, indicating its robustness as an early warning indicator of ECMO system obstructions.
- 4 August 2024
- Published by SAGE Publications in Perfusion
- Vol. 40 (4) , 941-946
Outcome of extracorporeal membrane oxygenation support among children with methicillin-resistant Staphylococcus aureus infection: A single-center experience
Introduction: The use of extracorporeal membrane oxygenation (ECMO) in children continues to increase nationally, including patients with methicillin-resistant Staphylococcus aureus (MRSA) infection. Survival of pediatric patients with MRSA sepsis has not improved over the last 20 years. We sought to review our institutional experience and outcomes of ECMO support among children with MRSA infection. Methods: Children aged 0–19 years who received ECMO support from October 2014 to June 2021 were reviewed retrospectively. Patients with laboratory confirmed MRSA infections were identified. Results: Out of 88 unique pediatric patients requiring ECMO support, eight patients had documented MRSA infections. The duration of mechanical ventilation prior to ECMO initiation was an average of seven days (range 0.7 to 21.8 days). The median ECMO duration was 648.1 h (range 15.5 to 1580.5 h). Five patients were successfully decannulated; however, only two patients survived to discharge. The two surviving patients were both cannulated via VV-ECMO. Mechanical ventilation prior to ECMO was 4.5 and 21.8 days in these cases with run durations of 18.9 and 29.9 days, respectively. Conclusions: Our institutional survival of patients with MRSA on ECMO is lower than what has been reported in recent database studies, but notably, 62.5% were successfully decannulated. While both surviving patients were supported with VV-ECMO, there was no other clear trend in factors that contributed to survival. MRSA continues to be a source of significant morbidity and mortality among pediatric patients. On-going investigation of outcomes and factors contributing to survival in patients with MRSA infection on ECMO is warranted.
- 4 August 2024
- Published by SAGE Publications in Perfusion
- Vol. 40 (4) , 941-946
Outcome of extracorporeal membrane oxygenation support among children with methicillin-resistant Staphylococcus aureus infection: A single-center experience
Introduction: The use of extracorporeal membrane oxygenation (ECMO) in children continues to increase nationally, including patients with methicillin-resistant Staphylococcus aureus (MRSA) infection. Survival of pediatric patients with MRSA sepsis has not improved over the last 20 years. We sought to review our institutional experience and outcomes of ECMO support among children with MRSA infection. Methods: Children aged 0–19 years who received ECMO support from October 2014 to June 2021 were reviewed retrospectively. Patients with laboratory confirmed MRSA infections were identified. Results: Out of 88 unique pediatric patients requiring ECMO support, eight patients had documented MRSA infections. The duration of mechanical ventilation prior to ECMO initiation was an average of seven days (range 0.7 to 21.8 days). The median ECMO duration was 648.1 h (range 15.5 to 1580.5 h). Five patients were successfully decannulated; however, only two patients survived to discharge. The two surviving patients were both cannulated via VV-ECMO. Mechanical ventilation prior to ECMO was 4.5 and 21.8 days in these cases with run durations of 18.9 and 29.9 days, respectively. Conclusions: Our institutional survival of patients with MRSA on ECMO is lower than what has been reported in recent database studies, but notably, 62.5% were successfully decannulated. While both surviving patients were supported with VV-ECMO, there was no other clear trend in factors that contributed to survival. MRSA continues to be a source of significant morbidity and mortality among pediatric patients. On-going investigation of outcomes and factors contributing to survival in patients with MRSA infection on ECMO is warranted.
- 21 July 2024
- Published by SAGE Publications in Perfusion
- Vol. 40 (4) , 898-906
EXCOR membrane motion analyzer (EMMA) to quantify and assess hemodynamic performance of the EXCOR pediatric heart assist device
Background: Pediatric heart failure is associated with high mortality rates and is a current clinical burden. There is only one FDA approved pediatric VAD, Berlin Heart EXCOR, for treatment. Thrombo-embolic complications are a significant clinical challenge, which can lead to devastating complications such as stroke and impair efficient EXCOR function. Currently, clinicians perform largely qualitative periodic assessment of EXCOR operation by observing the motion of a rapidly moving membrane, which can be prone to human error and can lead to missing out on crucial information. Methods: In this study, we design and implement a quantitative early warning system for accurate and quantitative assessment of the EXCOR membrane, named EXCOR Membrane Motion Analyzer (EMMA). Using a combination of image analysis, computer vision and custom designed algorithm, we perform rigorous frame by frame analysis of EXCOR membrane video data. We developed specialized metrics to identify relative smoothness between successive peaks, time between peaks and overall smoothness indicators to quantify and compare between multiple cases. Results: Our results demonstrate that EMMA can successfully identify the motion and wrinkles on each video frame and quantify the smoothness and identify the phases of each cardiac cycle. Moreover, EMMA can obtain the smoothness of each frame and the temporal evolution of membrane smoothness across all image frames for the video sequence. Conclusions: EMMA allows for a fast, accurate, quantitative assessment to be completed and reduces user error. This enables EMMA to be used effectively as an early warning system to rapidly identify device abnormalities.
- 21 July 2024
- Published by SAGE Publications in Perfusion
- Vol. 40 (4) , 898-906
EXCOR membrane motion analyzer (EMMA) to quantify and assess hemodynamic performance of the EXCOR pediatric heart assist device
Background: Pediatric heart failure is associated with high mortality rates and is a current clinical burden. There is only one FDA approved pediatric VAD, Berlin Heart EXCOR, for treatment. Thrombo-embolic complications are a significant clinical challenge, which can lead to devastating complications such as stroke and impair efficient EXCOR function. Currently, clinicians perform largely qualitative periodic assessment of EXCOR operation by observing the motion of a rapidly moving membrane, which can be prone to human error and can lead to missing out on crucial information. Methods: In this study, we design and implement a quantitative early warning system for accurate and quantitative assessment of the EXCOR membrane, named EXCOR Membrane Motion Analyzer (EMMA). Using a combination of image analysis, computer vision and custom designed algorithm, we perform rigorous frame by frame analysis of EXCOR membrane video data. We developed specialized metrics to identify relative smoothness between successive peaks, time between peaks and overall smoothness indicators to quantify and compare between multiple cases. Results: Our results demonstrate that EMMA can successfully identify the motion and wrinkles on each video frame and quantify the smoothness and identify the phases of each cardiac cycle. Moreover, EMMA can obtain the smoothness of each frame and the temporal evolution of membrane smoothness across all image frames for the video sequence. Conclusions: EMMA allows for a fast, accurate, quantitative assessment to be completed and reduces user error. This enables EMMA to be used effectively as an early warning system to rapidly identify device abnormalities.
- 23 November 2023
- Published by BMJ in BMJ Case Reports
- Vol. 16 (11) , e256265
Histoplasma associated pericarditis with pericardial tamponade in a child
Histoplasma-mediated pericarditis is rare, and it occurs due to host-mediated inflammatory or immune response to adjacent mediastinal adenitis or pneumonitis. It is usually self-limited and rarely progresses to a disseminated infection in an immunocompetent individual. In rare instances, it can occur without pulmonary manifestations, making the diagnosis challenging given the broad list of differentials that can be considered as in our patient who initially presented with an isolated pericardial effusion with tamponade needing emergent pericardiocentesis.
- 23 November 2023
- Published by BMJ in BMJ Case Reports
- Vol. 16 (11) , e256265
Histoplasma associated pericarditis with pericardial tamponade in a child
Histoplasma-mediated pericarditis is rare, and it occurs due to host-mediated inflammatory or immune response to adjacent mediastinal adenitis or pneumonitis. It is usually self-limited and rarely progresses to a disseminated infection in an immunocompetent individual. In rare instances, it can occur without pulmonary manifestations, making the diagnosis challenging given the broad list of differentials that can be considered as in our patient who initially presented with an isolated pericardial effusion with tamponade needing emergent pericardiocentesis.
- Open Access
- 8 September 2022
- Published by Springer Nature in Cureus
- Vol. 14 (9) , e28983
A Rare Presentation of New-Onset Type 1 Diabetes Mellitus in a Developmentally Delayed Child With an Overlap of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State
Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) are serious complications associated with diabetes mellitus (DM). HHS is a common diagnosis in adults but rare in children. DKA is a usual presentation for new-onset type 1 DM, although HHS is rarely a manifestation of new-onset type 1 DM. Diagnosis and management of HHS are challenging in pediatric patients, especially if they present with a mixed picture of HHS and DKA. We report an adolescent female with a new onset of type 1 DM presented as mixed DKA and HHS. Treatment included meticulous management of fluids and continuous insulin drip with the resolution of acidosis within 24 hours and hyperosmolar state at 96 hours of admission. Early differentiation of these two entities and meticulous fluid management improves the outcome and decreases the risk of complications such as cerebral edema, renal failure, and thrombosis, among others.
- 8 September 2022
- Published by Springer Nature in Cureus
- Vol. 14 (9) , e28983
Open AccessA Rare Presentation of New-Onset Type 1 Diabetes Mellitus in a Developmentally Delayed Child With an Overlap of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State
Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) are serious complications associated with diabetes mellitus (DM). HHS is a common diagnosis in adults but rare in children. DKA is a usual presentation for new-onset type 1 DM, although HHS is rarely a manifestation of new-onset type 1 DM. Diagnosis and management of HHS are challenging in pediatric patients, especially if they present with a mixed picture of HHS and DKA. We report an adolescent female with a new onset of type 1 DM presented as mixed DKA and HHS. Treatment included meticulous management of fluids and continuous insulin drip with the resolution of acidosis within 24 hours and hyperosmolar state at 96 hours of admission. Early differentiation of these two entities and meticulous fluid management improves the outcome and decreases the risk of complications such as cerebral edema, renal failure, and thrombosis, among others.
- 30 March 2022
- Published by SAGE Publications in Perfusion
- Vol. 38 (4) , 771-780
Risk factors for hemolysis with centrifugal pumps in pediatric extracorporeal membrane oxygenation: Is pump replacement an answer?
Introduction: Hemolysis during pediatric extracorporeal membrane oxygenation (ECMO) is associated with increased risk for renal failure and mortality. Objectives: We aim to describe risk factors for hemolysis in pediatric ECMO supported by centrifugal pumps. Methods: We conducted an analysis of retrospective data collected at an academic children’s hospital from January 2017 to December 2019. Measurements and results: Plasma-free hemoglobin (PFH) levels were measured daily, and hemolysis was defined as PFH>50 mg/dL. Of 46 ECMO runs over 528 ECMO days, hemolysis occurred in 23 (58%) patients over a total of 40 (8%) ECMO days. In multivariable logistic regression models, VA-ECMO (aOR=4.69, 95% CI: 1.01–21.83) and higher hemoglobin (aOR = 1.38, 95% CI: 1.06–1.81) were independently associated with hemolysis. There were also non-significant trends toward increased risk for hemolysis with higher rotational pump speed (aOR=2.39, 95% CI: 0.75–7.65), higher packed red blood cell transfusions (aOR=1.15, 95% CI: 0.99–1.34), and higher cryoprecipitate transfusions (aOR=2.01, 95% CI: 0.83–4.86). Isolated pump exchanges that were performed in 12 patients with hemolysis led to significant decreases in PFH levels within 24 h (89 vs 11 mg/dL, p <0.01). Conclusions: Hemolysis is common in pediatric ECMO using centrifugal pumps. Avoidance of high pump speeds and conservative administration of blood products may help to mitigate the risk for hemolysis. Furthermore, pump exchange may be an effective first-line treatment for hemolysis.
- 30 March 2022
- Published by SAGE Publications in Perfusion
- Vol. 38 (4) , 771-780
Risk factors for hemolysis with centrifugal pumps in pediatric extracorporeal membrane oxygenation: Is pump replacement an answer?
Introduction: Hemolysis during pediatric extracorporeal membrane oxygenation (ECMO) is associated with increased risk for renal failure and mortality. Objectives: We aim to describe risk factors for hemolysis in pediatric ECMO supported by centrifugal pumps. Methods: We conducted an analysis of retrospective data collected at an academic children’s hospital from January 2017 to December 2019. Measurements and results: Plasma-free hemoglobin (PFH) levels were measured daily, and hemolysis was defined as PFH>50 mg/dL. Of 46 ECMO runs over 528 ECMO days, hemolysis occurred in 23 (58%) patients over a total of 40 (8%) ECMO days. In multivariable logistic regression models, VA-ECMO (aOR=4.69, 95% CI: 1.01–21.83) and higher hemoglobin (aOR = 1.38, 95% CI: 1.06–1.81) were independently associated with hemolysis. There were also non-significant trends toward increased risk for hemolysis with higher rotational pump speed (aOR=2.39, 95% CI: 0.75–7.65), higher packed red blood cell transfusions (aOR=1.15, 95% CI: 0.99–1.34), and higher cryoprecipitate transfusions (aOR=2.01, 95% CI: 0.83–4.86). Isolated pump exchanges that were performed in 12 patients with hemolysis led to significant decreases in PFH levels within 24 h (89 vs 11 mg/dL, p <0.01). Conclusions: Hemolysis is common in pediatric ECMO using centrifugal pumps. Avoidance of high pump speeds and conservative administration of blood products may help to mitigate the risk for hemolysis. Furthermore, pump exchange may be an effective first-line treatment for hemolysis.